NCT00071396 - Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

September 30, 2006

Study Completion Date

August 31, 2007

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Campath-1H

15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.

DRUG

Rituximab

375 mg/m\^2 IV infusion on day 1, then 500 mg/m\^2 on days 8, 15, and 22.

Trial Locations (1)

77030

University of Texas - MD Anderson Cancer Center, Houston